Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: A national register-based study

Parkinsonism and Related Disorders

Volumn 20, Issue 11, 2014, Pages 1124-1128

  Frandsen, Rune ^a   Baandrup, Lone ^a   Kjellberg, Jakob ^b   Ibsen, Rikke ^c   Jennum, Poul ^a,d  

^a Mental Health Services CPH   (Denmark)

^b Dansk Sundhedsinstitut   (Denmark)

^c Itracks   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aging; Antipsychotics; Morbidities; National patient registry; Parkinson's disease; Psychotropic medication

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE LIKE DRUG; FIRST GENERATION ANTIPSYCHOTIC; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SECOND GENERATION ANTIPSYCHOTIC; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUSE OF DEATH; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PARKINSON DISEASE; POLYPHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; AGED; DENMARK; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; STATISTICS AND NUMERICAL DATA; SURVIVAL; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84908620343     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.07.012     Document Type: Article

References (23)

1. Seppi K., Weintraub D., Coelho M., Perez-Lloret S., Fox S.H., Katzenschlager R., et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011 Oct, 26(Suppl.3):S42-S80.
2. Marras C., Gruneir A., Wang X., Fischer H., Gill S.S., Herrmann N., et al. Antipsychotics and mortality in Parkinsonism. Am J Geriatr Psychiatry 2012 Feb, 20:149-158.
3. Kripke D.F., Langer R.D., Kline L.E. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012, 2:e000850.
4. Tiihonen J., Suokas J.T., Suvisaari J.M., Haukka J., Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012 May, 69:476-483.
5. Baandrup L., Gasse C., Jensen V.D., Glenthoj B.Y., Nordentoft M., Lublin H., et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. JClin Psychiatry 2010 Feb, 71:103-108.
6. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004 May 29, 363:1783-1793.
7. Braak H., Del T.K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 Mar, 24:197-211.
8. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006 Mar, 5:235-245.
9. Dissanayaka N.N., Sellbach A., Silburn P.A., O'Sullivan J.D., Marsh R., Mellick G.D. Factors associated with depression in Parkinson's disease. JAffect Disord 2011 Jul, 132:82-88.
10. Boeve B.F. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010 Jan, 1184:15-54.
11. Postuma R.B., Aarsland D., Barone P., Burn D.J., Hawkes C.H., Oertel W., et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012 Apr 15, 27:617-626.
12. Schenck C.H., Boeve B.F., Mahowald M.W. Delayed emergence of a parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behavior disorder (RBD): 16year update on a previously reported series. Sleep Med 2013 Aug, 14(8):744-748. Epub 2013 Jan 22.
13. Friedman J.H. Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning. Neurology 2006 Aug 22, 67:564-566.
14. World Health Orgianization International Classification of Diseases. Available from: http://www.who.int/classifications/icd/en/.
15. World Health Organization Anatomical Therapeutic Chemical Classification. WHO Collaborating Centre for Drug Statistics Methodology. Available from: http://www.whocc.no/.
16. Briesacher B.A., Limcangco M.R., Simoni-Wastila L., Doshi J.A., Levens S.R., Shea D.G., et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005 Jun 13, 165:1280-1285.
17. Poewe W., Gauthier S., Aarsland D., Leverenz J.B., Barone P., Weintraub D., et al. Diagnosis and management of Parkinson's disease dementia. Int J Clin Pract 2008 Oct, 62:1581-1587.
18. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005 Oct 19, 294:1934-1943.
19. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. JNeuropsychiatry Clin Neurosci 1996, 8:223-226.
20. Marti M.J., Tolosa E., Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003 Sep, 6(Suppl.18):S21-S27.
21. McKeith I., Fairbairn A., Perry R., Thompson P., Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992 Sep 19, 305:673-678.
22. Wermuth L., Lassen C.F., Himmerslev L., Olsen J., Ritz B. Validation of hospital register-based diagnosis of Parkinson's disease. Dan Med J 2012 Mar, 59:A4391.
23. Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002 Apr, 125:861-870.